|
Study phase, n (%)
|
|
Phase 1
|
17 (24)
|
12 (67)
|
|
Phase 2
|
38 (54)
|
6 (33)
|
|
Phase 3
|
16 (23)
|
0
|
|
Drug type, n (%)
|
|
Immune checkpoint inhibitors
|
18 (25)
|
1 (6)
|
|
Other anticancer drugs
|
53 (75)
|
17 (94)
|
|
Sample size, median (interquartile range)
|
102 (53–345)
|
42 (37–56)
|
|
Multi-country study, n (%)
|
46 (65)
|
5 (28)
|
|
Author affiliation with industry, n (%)
|
71 (100)
|
16 (89)
|
|
Statistically significant outcomeª, n (%)
|
17 (24)
|
0
|
|
Reporting of adverse events, n (%)
|
71 (100)
|
18 (100)
|
|
Selective outcome reporting, n (%)
|
8 (11)
|
7 (39)
|
